Business UpdateNov 3, 2026, 05:01 PM
NeOnc Technologies to Present NEO100 and NEO212 Data at Neuro-Oncology Meeting
AI Summary
NeOnc Technologies Holdings, Inc. announced that data from its intranasal NEO100 and oral NEO212 programs will be presented at the 31st Annual Meeting of the Society for Neuro-Oncology. The presentations will take place on November 13, 2026, in Philadelphia. The posters will cover updated results from a Phase 1/2a study and compassionate use experience for NEO100 in specific types of astrocytoma, as well as Phase 1 safety, PK, and early activity signals for NEO212 in TMZ-resistant recurrent GBM and brain metastases.
Key Highlights
- NeOnc Technologies will present data from its intranasal NEO100 program at the Society for Neuro-Oncology meeting.
- Data from NeOnc's oral NEO212 program will also be presented at the Society for Neuro-Oncology meeting.
- Presentations will occur on November 13, 2026, at the 31st Annual Meeting of the Society for Neuro-Oncology in Philadelphia.
- The NEO100 poster will detail updated results from a Phase 1/2a study and compassionate use experience in recurrent WHO Grade III/IV IDH1-Mutant Astrocytoma.
- The NEO212 poster will cover Phase 1 safety, PK, and early signals of activity in TMZ-resistant recurrent GBM and brain metastases.
Price Impact
More from NTHI